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Abstract
AIM: To investigate plasma microRNA (miRNA) profiles 
indicative of hepatotoxicity in the setting of lethal acet-
aminophen (APAP) toxicity in mice. 
METHODS: Using plasma from APAP poisoned mice, 
either lethally (500 mg/kg) or sublethally (150 mg/kg) 
dosed, we screened commercially available murine mi-
croRNA libraries (SABiosciences, Qiagen Sciences, MD) 
to evaluate for unique miRNA profiles between these 
two dosing parameters. 
RESULTS: We distinguished numerous, unique plasma 
miRNAs both up- and downregulated in lethally com-
pared to sublethally dosed mice. Of note, many of 
the greatest up- and downregulated miRNAs, namely 
574-5p, 466g, 466f-3p, 375, 29c, and 148a, have been 
shown to be associated with asthma in prior studies. 
Interestingly, a relationship between APAP and asthma 
has been previously well described in the literature, 
with an as yet unknown mechanism of pathology. 
There was a statistically significant increase in alanine 
aminotransferase levels in the lethal compared to sub-
lethal APAP dosing groups at the 12 h time point (P  < 
0.001). There was 90% mortality in the lethally com-
pared to sublethally dosed mice at the 48 h time point (P  
= 0.011). 
CONCLUSION: We identified unique plasma miRNAs 
both up- and downregulated in APAP poisoning which 
are correlated to asthma development.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Acetaminophen (APAP) continues to be an important 
cause of  acute liver failure in the developed world, second 
only to infectious etiologies worldwide[1]. It is also the 
most common cause of  death due to analgesic ingestion 
in the United States[2]. Numerous emergency department 
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patients in the setting of  acetaminophen overdose are ad-
mitted to hospital for N-acetylcysteine (NAC) treatment. 
This necessary treatment modality places these patients 
at risk for health-care associated disease. It also places 
likely unnecessary additional financial strain on an already 
burdened healthcare system. In addition, the estimated 
United States cost of  treating intentional acetaminophen 
overdose is $86.9 million per year[3]. However, in over 30 
years of  research it is still unclear how the exact mecha-
nism of  acetaminophen toxicity occurs[4]. 
Current literature implicates N-acetyl-para-benzoqui-
none-imine, or N-acetyl-p-benzoquinoneimine (NAPQI), 
as the primary metabolite responsible for hepatotoxicity. 
An estimated 90% of  APAP is metabolized in the liver via 
either glucuronidation or sulfation. Another approximate 
5% is urinated unaltered. However, approximately 5% of  
APAP is metabolized by the cytochrome P450 2E1 path-
way into NAPQI. In the scenario of  APAP overdose, the 
normal route of  metabolism becomes overburdened, so 
an overabundance of  NAPQI is produced, causing hepa-
totoxicity. Glutathione can rescue this process, and is the 
reason NAC is used as a treatment modality. However, it is 
presumed only a portion of  hepatotoxicity occurs via this 
mechanism. Lipid peroxidation via free radical formation, 
and mitochondrial dysfunction via increased permeability 
of  the mitochondrial permeability transition, are also pos-
tulated as causes of  APAP-associated hepatotoxicity[5,6]. 
Clearly, a better understanding of  how APAP spe-
cifically causes hepatic toxicity from a pathophysiologic 
perspective still needs to be determined. In addition, 
standard clinical laboratory testing may not reveal evi-
dence of  hepatic injury for up to 24 h following APAP 
ingestion. A considerable proportion of  APAP-exposed 
individuals therefore receive unnecessary empiric treat-
ment with an antidote before hepatic injury can be ruled 
out. To overcome this clinical problem, early diagnostic 
indicators of  hepatic injury have been sought.
MicroRNA fragments (miRNAs), are short, chemi-
cally stable biomolecules, noncoding posttranslational 
regulators that bind to untranslated mRNA sequences 
to produce gene silencing[7-10]. Moreover, each miRNA 
targets several different mRNAs; the same target gene 
may be regulated by several different miRNAs in differ-
ent biological situations, a process that allows enormous 
complexity and flexibility in their regulatory potential. 
miRNAs have been characterized as regulators of  protein 
expression in diverse disease processes, including acute 
hepatic injury[9,10]. Importantly, miRNAs have already 
been successfully utilized as early biomarkers for esopha-
geal squamous cell carcinoma detection in serum[7], 
identifying Parkinson’s disease onset and disease progres-
sion[8], and diagnosis of  hepatocarcinoma[9,10], demon-
strating miRNAs as an ideal area of  research to deter-
mine other early biomarkers for disease states, notably 
APAP-associated hepatotoxicity[11]. In addition, miRNA 
fragments do not require the post-translational modifica-
tions necessary in protein production; with fewer human 
miRNAs to evaluate (an estimated 1000 human miRNAs 
compared to approximately 20  000 proteins), there is an 
improved likelihood of  identifying unique APAP-associ-
ated miRNA profiles[11]. 
Recent work has also shown the medical utility of  
miRNA[12,13]. Interestingly, literature also supports its as-
sociation specifically in the setting of  acetaminophen 
toxicity. For instance, Wang et al[11] (2009) showed in-
creased levels of  miR-122 and miR-192 in the plasma 
of  acetaminophen overdosed mice, yet decreased levels 
of  these miRNAs in the liver tissue. In addition, these 
determined markers changed with time and dosing cor-
responding to histologic liver damage. Of  note, these 
profiles were not evaluated at the lethal APAP dosing of  
500 mg/kg, a parameter requiring further investigation to 
specifically compare lethal and sublethal miRNA profiles. 
Furthermore, additional literature has described miRNA 
involvement in acetaminophen toxicity, as well as the 
utility of  miRNAs as biomarkers useful in the setting of  
other hepatotoxic disorders, such as hepatitis B and C, al-
coholic liver disease, non-alcoholic fatty liver disease, and 
primary biliary cirrhosis[14]. 
However, these miRNAs could be a potential marker 
for liver toxicity in the human patient as well, specifically 
in the setting of  acetaminophen overdose. The identifica-
tion of  early plasma markers of  acetaminophen toxicity 
is necessary and paramount. Early identification of  acet-
aminophen toxicity would identify those requiring more 
expeditious treatment, potentially improving morbidity 
and mortality of  these individuals. It would also possibly 
abrogate the need for patient admission, mitigating the 
resultant financial system burden and iatrogenic risk of  
hospital-acquired infections. 
MATERIALS AND METHODS
Acetaminophen toxicity
C57Bl/6 wild-type mice were purchased from Jackson 
Laboratory (Bar Harbor, ME) and received proper care in 
agreement with animal protocols approved by the Institu-
tional Animal Use and Care Committee of  the University 
of  Massachusetts Medical School.
For all experiments, 6-wk-old female C57/BL6 mice, 
with food deprivation 12 h prior to experimentation, 
were used for intraperitoneal (ip) injections. For lethal 
dosing APAP experiments, 20 C57/BL6 mice were each 
injected with acetaminophen 500 mg/kg (0.9% normal 
saline suspension) ip at time zero. For the sublethal dos-
ing APAP experiments, 20 C57/BL6 mice were injected 
with acetaminophen 150 mg/kg acetaminophen (0.9% 
normal saline suspension) ip at time zero. At times 0.5 h, 
2 h, 12 h, 24 h, and 48 h, 5 mice per group (both lethal 
and sublethal) were sacrificed via cervical dislocation. Just 
prior to sacrifice, 400 mL of  cheek blood was obtained 
from each mouse. The whole blood was then centrifuged 
at 14  000 g for 10 min at room temperature. The plasma 
was removed, aliquoted, and stored at -80  ℃. After sacri-
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fice, livers were snap frozen in liquid nitrogen for protein, 
stored in RNA stabilization reagent (RNAlater, Qiagen, 
Hilden, Germany) for RNA extraction, or fixed in 10% 
neutral-buffered formalin for histopathologic analysis. 
Five mice were injected with saline only ip and sacrificed 
at time 48 h as controls. 
Hepatotoxicity verification
Alanine aminotransferase (ALT) was quantified by bio-
chemical assay (D-Tek Analytical Laboratories Inc, San 
Diego, CA). 
Survival studies
Ten mice were injected with APAP 500 mg/mL ip and an 
additional 10 mice were injected with APAP 150 mg/mL, 
all at time zero. Mice were monitored for 48 h and the 
mortality for each recorded and plotted using Kaplan-
Meier survival statistics (GraphPad Prism Software, LaJol-
la, CA). All mice were housed, watered and fed under the 
same conditions throughout the experimental protocol.
Histopathologic analysis
Sections of  formalin-fixed, paraffin-embedded livers af-
ter sublethal and lethal APAP dosing were stained with 
hematoxylin and eosin and assessed for inflammatory 
infiltrate calculated with Microsuite (Olympus Soft Imag-
ing Solution GmbH, Munster, Germany) image analysis 
software in 20 X objective. 
MicroRNA library screen
MicroRNA was purified from plasma using the MiR-
Neasy Mini kit (Qiagen Sciences, MD). The cDNA was 
prepared using (reverse transcriptase2) RT2 First Strand 
cDNA kit (SABiosciences, Qiagen Sciences, MD). The li-
braries were screened using pooled plasma samples from 
the 12 h time point for each APAP dosing parameter us-
ing saline injected mice as controls (5 mice/group). The 
screening libraries utilized were the RT2 miRNA PCR 
arrays for mouse whole genome, per the manufacturer’
s protocol (SABiosciences, Qiagen Sciences, MD). Real-
time quantitative polymerase chain reaction (QPCR) was 
performed using RT2 QPCR SYBR green MasterMix 
(SABiosciences, Qiagen Sciences, MD) and the iCycler iQ 
Cycler (Bio-Rad Laboratories, Inc, Hercules, CA). 
QPCR data were analyzed using manufacturer soft-
ware (http://pcrdataanalysis.sabiosciences. com/pcr/ar-
rayanalysis.php). 
RESULTS
APAP toxicity confirmation: ALT levels and survival
Numerous plasma miRNAs were both upregulated and 
downregulated, respectively, for the lethally compared to 
sublethally dosed APAP mice (Figure 1). Increase in se-
rum levels of  ALT is a well characterized marker of  liver 
injury in the clinical setting as well as in animal models. 
Hepatotoxicity induced by APAP administration in our 
experiments was confirmed utilizing an ALT assay. An 
ALT average for the sublethal APAP dosing (150 mg/
kg) peaked at 883 IU/L and for the lethal APAP dosing 
(500 mg/kg) peaked at 7396 IU/L, both at 24 h (Figure 
2). There was a statistically significant increase in ALT 
levels in the lethal dosing compared to the sublethal dos-
ing groups (642 IU/L compared to 6796 IU/L, respec-
tively) starting at the 12 h time point (P < 0.001). There 
remained statistically significant increased ALT levels 
for both the sublethal and lethal dosed groups at the 48 
h time point compared to the 0.5 h and 2 h time points 
(Figure 2). 
With administration of  a high dose APAP (500 mg/
kg), we found that there was 90% lethality compared to 
no lethality with the sublethal dosing (150 mg/kg) at the 
48 h time point as demonstrated by the nonparametric 
maximum likelihood estimate of  a Kaplan-Meier survival 
curve (Figure 3). This difference was statistically signifi-
cant at P = 0.011, with ten mice utilized per dosing pa-
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Figure 1  Plasma microRNA both up- and downregulated in lethally (500 
mg/kg) compared to sublethally (150 mg/kg) dosed acetaminophen mice 
at the 12 h time point. A total of 528 microRNAs were screened using the 
reverse transcriptase2 miRNA polymerase chain reaction (PCR) array of mouse 
whole genome, per the manufacturer’s protocol (SABioscience, Qiagen Sci-
ences, MD). Quantitative PCR data were analyzed using manufacturer software 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). 
500 mg/kg
150 mg/kg
a
a a
a
9
6
3
0
AL
T 
×
 1
03
 (
U
/L
)
0.5                2                 12               24                48
                                       t /h
Figure 2  Increased hepatotoxicity (measured in elevated alanine amino-
transferase levels) in lethally dosed acetaminophen mice over time. aP < 
0.05 vs 0.5 h time point for the 150 mg/kg and 500 mg/kg treatment groups, 
respectively. ALT: Alanine aminotransaminase.
Ward J et al . Plasma microRNAs and acetaminophen toxicity
2801 June 14, 2012|Volume 18|Issue 22|WJG|www.wjgnet.com
larged hepatocytes and highly vacuolated cytoplasm. The 
lethal dosed liver also demonstrated pyknotic nuclei with 
extensive ballooning vacuolar degeneration (Figure 4B). 
MicroRNA profile of APAP toxicity
In an attempt to evaluate plasma miRNAs as potential 
indicators of  APAP-induced liver damage, we screened 
plasma of  mice after administration of  a lethal or sub-
lethal dose of  APAP. Out of  the 528 murine miRNAs 
analyzed, there were more than 40 potential miRNAs 
that were both greater than 2-fold up- and downregulated 
in the lethal (500 mg/kg) compared to sublethal (150 
mg/kg) dosing (Table 1). The miRNAs listed were ef-
fectively detected suggesting the actual fold-change value 
is as large as the calculated and reported fold-change 
result (SABiosciences, Qiagen Sciences, MD). The small 
nucleolar RNA, C/D Box 68 (Snord68), was used as the 
internal control for each library evaluated. 
Finally, we performed an extensive literature search 
to gather information on the known and putative targets 
of  12 miRNAs that were uniquely changed in the plasma 
after administration of  the lethal dose of  APAP (Table 2). 
Interestingly, we found 6 out of  the top 12 miRNAs with 
the greatest fold change (both up- and downregulated) 
in the lethally compared to sublethally dosed APAP mice 
were associated with asthma. The other miRNAs found 
both highly up- and downregulated were found to be as-
sociated with hypoxia-inducible factor (HIF)-1[15], follicle 
stimulating hormone[16], type 1 diabetes[17], procollagen 
type Ⅲ[18], colon cancer[19], gastric carcinoma[20], and elon-
gation factor 2 tumor suppression[21] (Table 2). 
DISCUSSION
Our study reveals numerous miRNAs, notably 574-5p, 
135a*, 466g, 1196, 466f-3p, and 877, are upregulated 
rameter analyzed (Graphpad Prism Software; LaJolla, CA).
APAP toxicity confirmation: Histology 
For the sublethally dosed mice, the portal and periportal 
regions appear normal, with no signed of  centrilobular 
necrosis or inflammation (Figure 4A). However, for the 
lethally dosed mice, obvious extensive centrilobular necro-
sis and inflammation were present, with distinctively en-
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Figure 3  Survival of lethally compared to sublethally dosed acetamino-
phen mice. Kaplan-Meier survival curve over time (h) after sublethal (150 
mg/kg) and lethal (500 mg/kg) acetaminophen poisoning (P = 0.011). 
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                           Hours after APAP injection
Figure 4  Histopathologic analysis of liver after lethal compared to sub-
lethal acetaminophen dosing. Hematoxylin and eosin liver tissue staining 
at 12 h of (A) sublethally (150 mg/kg) acetaminophen poisoned mice, with no 
signs of centrilobular inflammation or necrosis; and (B) lethally (500 mg/kg) 
acetaminophen poisoned mice with extensive centrilobular necrosis, enlarged 
hepatocytes, and highly vacuolated cytoplasm. 
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Table 1  Greatest fold plasma microRNA changes in lethally 
dosed acetaminophen mice
MicroRNA Fold increase MicroRNA Fold decrease
574-5p 203.7 342-3p 0.0005
135a* 173.6 195 0.0041
466g 110.7 375 0.0085
1196   82.7 29c 0.0134
466f-3p              71 148a 0.0152
877   64.4 652 0.0199
139-3p   59.7 202-5p 0.0317
686   48.8 200a           0.039
346   47.5 320 0.0422
149   34.9 374* 0.0508
485   34.5 9* 0.0556
409-3p   30.7 342-5p 0.0629
202-3p   28.1 192 0.0656
298   27.4 412 0.0713
15a   27.1 1 0.0775
341   26.2 199b 0.0775
296-3p   24.3 741 0.0902
466i   22.1 100 0.1145
1186   21.4 18b 0.1604
200a   20.5 122 0.2348
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in the setting of  lethal compared to sublethal APAP-
associated hepatotoxicity, whereas miRNAs 342-3p, 195, 
375, 29c, 148a and 652 are markedly downregulated. We 
demonstrate elevated ALT levels as well as histologic evi-
dence supporting worsened hepatotoxicity in the setting 
of  lethally dosed mice compared to non-lethally dosed 
mice (Figures 2 and 4). With 90% lethality in the lethally 
dosed mice in relation to no lethality in sublethally dosed 
mice (P = 0.0011), this supports the premise that unique 
plasma miRNA profiles may correlate with non- vs life-
threatening APAP dosing (Figure 3). The fold-change 
of  a variety of  miRNAs in the setting of  lethally dosed 
mice compared to sublethal doses is of  interest. Of  note, 
more than 40 were both up- and downregulated, with the 
greatest fold miRNA changes reported (Table 1). 
A literature search to investigate possible functions of  
the miRNAs both up- and downregulated was undertak-
en. Intriguingly, many of  those most up- and downregu-
lated in the lethally compared to sublethally dosed mice, 
namely 574-5p, 466g, 466f-3p, 375, 29c, and 148a, have 
also been implicated in the development of  asthma[22,23]. 
For instance, 574-5p may be involved with asthma patho-
genesis, with decreased miRNA 574-5p in chronic com-
pared to acute asthma in a mouse model sensitized with 
ovalbumin[23]. In another study, a potential relationship 
between histocompatibility antigen-G, chronic asthma, 
and miRNA 29c was determined[22]. This consequently 
suggests a pathophysiologic relationship between APAP 
toxicity and asthma[22,23]. 
Interestingly, prior research has shown an association 
between APAP use and asthma although the exact as-
sociation is still unclear[24,25]. For instance, an adult case 
control study described a relationship between acetamin-
ophen use and asthma[26]. Additional literature revealed 
an increased risk of  wheeze in children whose mothers 
used prenatal APAP[27]. The etiology still remains unclear. 
However, one theory is that decreased glutathione (due 
to depletion secondary to APAP toxicity) provides the 
opportunity for unchecked reactive oxygen species to 
promote asthma development[24]. Additional theories in-
clude increased prostaglandin E2 production secondary 
to elevated cyclooxygenase-2 activity in the presence of  
APAP promoting a T2 allergic response[25]. A third cause 
could be direct lung damage from NAPQI, a byprod-
uct of  APAP metabolism[28]. Clearly, more information 
is needed to further elucidate the relationship between 
APAP and risk of  asthma. 
The previous literature describing the function of  
the other miRNAs up- and downregulated in our study 
is more varied. For example, some literature reveals a 
miRNA 135a association with HIF 1-α[15]. Interestingly, 
previous literature has demonstrated HIF 1-α induction 
prior to APAP toxicity in the setting of  lethal APAP dos-
ing, with toxicity prevented by the presence of  cyclospo-
rine A, a HIF 1-α inhibitor which prevents mitochondrial 
permeability transition and oxidative stress[29]. Additional 
studies have also shown elevation of  HIF 1-α in the set-
ting of  APAP toxicity, with increased HIF 1-α causing 
increased glucose transporter-1 expression[30]. Of  note, 
miRNAs 195 and 342-3p have been shown as involved 
with hepato cytopathology in the setting of  tumor sup-
pression in hepatocellular carcinoma models[21] and hepa-
titis B virus hepatocarcinoma diagnosis[10], respectively. 
However, how these miRNAs in total affect hepato-
toxicity in the setting of  APAP poisoning still needs to 
be elucidated. Prior studies reveal upregulation of  plasma 
miR-122 in the setting of  APAP-associated liver toxic-
ity, while our data suggest downregulation of  plasma 
miR-122 at the 12 h time point. This discrepancy could 
be potentially explained by examination of  upregulation 
of  miR-122 at 1 h, 3 h and 24 h time points, not at a 12 
h time point in previous literature. In addition, different 
APAP dosing levels were used in each study (300 mg/kg 
compared to 500 mg/kg), again demonstrating the dy-
namic nature of  miRNA regulation across both time and 
clinical setting[11]. Of  note, we found upregulation of  
plasma miR-298 and miR-370, whereas other researchers 
found downregulation of  these miRNAs in the setting 
of  APAP-associated hepatotoxicity[31]. Again, this may be 
due to evaluation at different time points (6 h compared 
to 12 h) and differing APAP dosing parameters (1000 
mg/kg compared to 500 mg/kg)[31]. Together, these re-
sults demonstrate the need for further identification of  
additional plasma microRNA profiles at various time 
points and dosing levels. 
Our ultimate goal would be to eventually have a miR-
NA APAP nomogram to be used for human patient care, 
similar to the previous effective Rumack-Matthew no-
mogram[32,33]. The problem with this current nomogram, 
however, is that it relies on knowing when a patient ini-
tially ingested APAP. This is often difficult, if  patients are 
poor historians or have ingested mind-altering substances 
Table 2  Lethal acetaminophen associated plasma microRNAs 
and potential correlative function
MicroRNA Function
574-5p Acute and chronic asthma (Garbacki et al[23]); 
Procollagen type Ⅲ A1 (Sterling[18])
135a Hypoxia-inducible factor-1 and nuclear factor-κB 
production (Gonsalves et al[15]) 
466g Acute and chronic asthma (Garbacki et al[23])
1196 Follicle-stimulating hormone regulation (Yao et al[16])
466f-3p Acute and chronic asthma (Garbacki et al[23]); 
Procollagen type Ⅲ A1 (Sterling[18])
877 Human type 1 diabetes (Zhou et al[17])
139-3p Colon and rectal cancer (Slattery et al[19])
342-3p HBV infection and HBV-positive hepatocarcinoma 
biomarker (Li et al[10])
195 E2F tumor suppressor (Xu et al[21])
375 Acute and chronic asthma (Garbacki et al[23]); 
Pyruvate dehydrogenase kinase inhibition in gastric 
carcinomas (Tsukamoto et al[20]) 
29c Acute and chronic asthma (Garbacki et al[23])
148a HLA-G and risk asthma (Tan et al[22])
HBV: Hepatitis B virus; E2F: Elongation factor 2; HLA-G: Human leuko-
cyte antigen-G.
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such as alcohol at the time of  evaluation. In addition, 
patients may have been taking APAP chronically, not 
acutely, making use of  the Rumack-Matthew nomogram 
pointless. The importance of  our work is to establish 
a novel miRNA nomogram that would be used for pa-
tients who have taken APAP at an unknown time or with 
chronic ingestions. In turn, this would avoid investigation 
of  patients who have taken it chronically, thus preventing 
unnecessary treatment and iatrogenic ingestions. Addi-
tional studies in this field, with additional time points and 
dosing levels, however, are clearly still necessary. 
The specificity of  this profile also requires further im-
provement. For instance, in a recent report miRNA-122 
was shown to be increased in the setting of  APAP toxic-
ity, although this increase was under the detection cut-off  
of  our study[11]. Of  note, miRNA-122 is also upregulated 
in hepatitis C settings which, by itself, is evidently not 
specific enough to uniquely identify APAP toxicity[14]. 
However, with additional future studies and data analysis, 
this may possible. This approach may also be used as 
a model to develop profiles for additional disease pro-
cesses, namely non-alcoholic fatty liver disease and hepa-
tocellular carcinoma, since microRNA profiles are already 
being used as early biomarkers for numerous pathologic 
states[9,10]. Together, this may improve the diagnostic ac-
curacy of  hepatopathology, namely early APAP-induced 
hepatotoxicity. In turn, this may allow clinicians to better 
and more rapidly distinguish which patients who have in-
gested APAP will actually mandate therapy. Subsequently, 
this may result in decreasing the number of  patients who 
receive unnecessary, expensive empiric treatment.
In conclusion, lethal dosing of  APAP in a murine 
model is consistent with hepatotoxicity and up- and 
downregulation of  a unique pattern of  circulating plasma 
miRNAs, which is different from the plasma miRNA 
profile associated with sublethal APAP dosing. These dif-
ferences may be useful in the future to distinguish lethal 
and sublethal APAP toxicity in humans. 
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at the time of evaluation, or have been chronically ingesting APAP.
Terminology
Recent work has also shown the medical utility of miRNA. miRNAs, are short, 
chemically stable biomolecules that produce gene silencing. Furthermore, ad-
ditional literature has described miRNA involvement in acetaminophen toxicity, 
as well as the utility of miRNAs as biomarkers. 
Peer review
The manuscript provides some interesting information on the potential use of 
miRNAs for the early diagnosis of APAP associated liver toxicity. The scientific 
goal of the study has significant clinical application but the interpretation of the 
data needs to be revised.
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